Investigational drug · Phase 3
BCD-248
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Relapsed/Refractory Multiple Myeloma, Myeloma Multiple.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "BCD-248"
First trial start
2024
Dec 26, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BCD-248", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsed/Refractory Multiple Myeloma
- Myeloma Multiple
Approved drugs for the same conditions: Multiple myeloma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "BCD-248" as an intervention, largest first.
- A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)Pivotal-lookingRecruiting
BiocadIndustry
NCT07742215 · 390 participants (planned) · Start Jun 15, 2026 · Primary completion Jul 2028
Drug: BCD-248 + daratumumab; Daratumumab + pomalidomide + dexamethasone · For: Myeloma Multiple
Sites: Homyel, Belarus; Chelyabinsk, Russia; Irkutsk, Russia · 16 sites in all
BiocadIndustry
NCT06668792 · 100 participants (planned) · Start Dec 26, 2024 · Primary completion Feb 2026
Drug: BCD-248 · For: Relapsed/Refractory Multiple Myeloma
Sites: Kaliningrad, Russia; Kazan', Russia; Kirov, Russia · 20 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Relapsed/Refractory Multiple Myeloma
- AZD0120GC012FPhase 39 trials
AstraZeneca · Newly Diagnosed Multiple Myeloma (NDMM), Relapsed AL Amyloidosis, Refractory AL Amyloidosis
- SG301Phase 33 trials
Hangzhou Sumgen Biotech Co., Ltd. · Systemic Lupus Erythematosus (SLE), Relapsed/Refractory Multiple Myeloma, Antibody Mediated Rejection
- Eque-celFully Human BCMA Chimeric Antigen Receptor Autologous T CellPhase 21 trial
Nanjing IASO Biotechnology Co., Ltd. · Relapsed/Refractory Multiple Myeloma
- LBL-034Phase 21 trial
Nanjing Leads Biolabs Co.,Ltd · Relapsed/Refractory Multiple Myeloma
- REGN7945Phase 21 trial
Regeneron · Relapsed/Refractory Multiple Myeloma
- SG2918Phase 21 trial
Hangzhou Sumgen Biotech Co., Ltd. · Relapsed/Refractory Multiple Myeloma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.